Home › Funds › Kynam Capital Management, LP › PCVX

Kynam Capital Management, LP position in PCVX

VAXCYTE INC · Health Care

Kynam Capital Management, LP reported holding 2,922,335 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$169.9M, representing 9.39% of its reported portfolio and ranking #3 among its reported holdings. Kynam Capital Management, LP has disclosed PCVX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.92M sh
Reported value held$169.88M
Portfolio Weight9.39%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Kynam Capital Management, LP's PCVX position evolved

Kynam Capital Management, LP first disclosed a stake in PCVX in Q3 2023 at 1,302,407 shares (US$66.4M). The position peaked in Q4 2024 at 2,336,796 shares, worth US$191.3M. Across 12 filings, Kynam Capital Management, LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,922,335 shares valued at US$169.9M. Notable position changes include a 38% increase in Q3 2024 (shares fell 28% over the following quarter), a 125% increase in Q4 2024 (shares fell 54% over the following quarter), a 37% increase in Q1 2025 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.30M $66.40M New
Q4 2023 1.00M $62.95M Reduce
Q1 2024 745.00K $50.89M Reduce
Q2 2024 753.24K $56.88M Add
Q3 2024 1.04M $118.76M Add
Q4 2024 2.34M $191.29M Add
Q1 2025 3.20M $120.83M Add
Q2 2025 3.07M $99.86M Reduce
Q3 2025 3.07M $110.64M Hold
Q4 2025 2.92M $134.84M Reduce
Q1 2026 2.92M $169.82M Hold
Q2 2026 2.92M $169.88M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 35 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has Kynam Capital Management, LP held PCVX?

Kynam Capital Management, LP has disclosed PCVX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Kynam Capital Management, LP's current position in PCVX?

As of Q2 2026, Kynam Capital Management, LP holds 2.92M shares of PCVX (VAXCYTE INC), valued at $169.88M, representing 9.39% of its reported portfolio and ranking #3.

Has Kynam Capital Management, LP been buying or selling PCVX?

In the latest 13F filing (Q2 2026), Kynam Capital Management, LP held unchanged its position in PCVX. The position peaked in Q4 2024 at 2.34M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.